Protagonist Therapeutics Ownership
| PTGX Stock | USD 52.53 0.12 0.23% |
Shares in Circulation | First Issued 2016-09-30 | Previous Quarter 62 M | Current Value 65 M | Avarage Shares Outstanding 37.1 M | Quarterly Volatility 17.4 M |
Protagonist |
Protagonist Stock Ownership Analysis
About 99.0% of the company shares are owned by institutional investors. The book value of Protagonist Therapeutics was at this time reported as 11.06. The company had not issued any dividends in recent years. Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Protagonist Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 127 people. To find out more about Protagonist Therapeutics contact Dinesh Patel at 510 474 0170 or learn more at https://www.protagonist-inc.com.Protagonist Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Protagonist Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Protagonist Therapeutics backward and forwards among themselves. Protagonist Therapeutics' institutional investor refers to the entity that pools money to purchase Protagonist Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Perceptive Advisors Llc | 2024-12-31 | 1.3 M | Adar1 Capital Management Llc | 2024-12-31 | 1 M | Deep Track Capital, Lp | 1000 K | Wellington Management Company Llp | 2024-12-31 | 940.1 K | American Century Companies Inc | 2024-12-31 | 928.3 K | Goldman Sachs Group Inc | 2024-12-31 | 758.7 K | Amvescap Plc. | 2024-12-31 | 739 K | Eversept Partners, Llc | 2024-12-31 | 678.8 K | Northern Trust Corp | 2024-12-31 | 628.6 K | Blackrock Inc | 2024-12-31 | 9.9 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 5.9 M |
Protagonist Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protagonist Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protagonist Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protagonist Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protagonist Therapeutics Outstanding Bonds
Protagonist Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protagonist Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protagonist bonds can be classified according to their maturity, which is the date when Protagonist Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View | |
| PRXNA 3257 19 JAN 27 Corp BondUS74365PAG37 | View |
Protagonist Therapeutics Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of March 2025 An amendment to a previously filed Form 8-K | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.